

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/207615 A1

(51) International Patent Classification:

C07K 14/20 (2006.01) A61P 31/00 (2006.01)

A61K 39/02 (2006.01) A61P 31/04 (2006.01)

(21) International Application Number:

PCT/US2021/026599

(22) International Filing Date:

09 April 2021 (09.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20169148.2 09 April 2020 (09.04.2020) EP

20169147.4 09 April 2020 (09.04.2020) EP

20169642.4 15 April 2020 (15.04.2020) EP

20187283.5 22 July 2020 (22.07.2020) EP

20202816.3 20 October 2020 (20.10.2020) EP

63/152,582 23 February 2021 (23.02.2021) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(71) Applicants: VALNEVA AUSTRIA GMBH [AT/AT]; Campus Vienna Biocenter 3, 1030 Vienna (AT). PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors: BÉZAY, Nicole; Roseggersteig 3, 2371 Hinterbrühl (AT). HOCHREITER, Romana; Apostelgasse 24/21, 1030 Vienna (AT). LUNDBERG, Urban; Badgasse 6a/1/02, 3013 Pressbaum (AT). BAILEY, Steven, Russell; c/o Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426 (US). ANDERSON, Annaliesa, Sybil; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965 (US). JANSEN, Kathrin, Ute; c/o Pfizer Inc., 401 N. Middletown Road, Pearl River, NY 10965 (US). SCOTT, Daniel, Alfred; c/o Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426 (US).

(74) Agent: VAN AMSTERDAM, John, R. et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS COMPRISING THREE OSP A FUSION PROTEINS FOR MEDICAL USE

(57) Abstract: The present invention relates to a composition comprising the OspA fusion protein of SEQ ID NO: 1 (LipSID1-S2D1), the OspA fusion protein of SEQ ID NO: 2 (Lip-S4D1-SShybD1) and the OspA fusion protein of SEQ ID NO: 3 (Lip-S5D1-S6D1) for use in a vaccine or for use in a method for eliciting an immune response in a human against Lyme disease.

WO 2021/207615 A1